Introduction
============

With the continuous improvement of living standards in China, the incidence of non-alcoholic fatty liver disease (NAFLD), a disease previously almost exclusive of Western countries, has been increasing year by year, and it has become one of the most common liver diseases affecting human health ([@b1-etm-0-0-5476],[@b2-etm-0-0-5476]). Studies have shown that NAFLD can lead to metabolic disorders and diseases, which are closely related to hypertension and coronary heart disease ([@b3-etm-0-0-5476]). Cardiac bypass surgery and coronary stent implantation are common effective surgical treatments for coronary heart disease. But a series of adverse cardiovascular events after surgery still seriously threaten the life and health of those patients. Studies have shown that the bypass surgery induces the production and release of inflammatory factors in patients with coronary heart disease, affecting the prognosis of patients with coronary heart disease after surgery ([@b4-etm-0-0-5476]--[@b6-etm-0-0-5476]). At present, there are few studies on the relationship between the changes in inflammatory factors and the prognosis of coronary heart disease patients complicated with NAFLD after bypass surgery. In this study, the changes in expressions levels of inflammatory factors in peripheral blood of coronary heart disease patients complicated with NAFLD at different time-points before and after bypass surgery were investigated and their relationship to the patient prognosis were assessed, in order to provide a theoretical basis for clarifying mechanisms at play.

Patients and methods
====================

### Patients

The subjects in this study were a total of 68 patients were admitted to Xinjiang Hospital due to stable angina pectoris from August 2013 to August 2015 scheduled to undergo coronary artery bypass grafting (CABG). There were 30 males and 38 females aged 53--87 years. Diagnostic criteria for stable angina pectoris included the fact that the conditions of onset did not change within 1--3 months, the daily and weekly onset frequencies were roughly similar, the fatigue and degree of pain were stable, and the nature and site of pain were the same in every attack. Diagnostic criteria for NAFLD included histological changes in liver biopsy conformed to the pathological or imaging criteria of fatty liver disease, and the fact that patients had no alcohol drinking history or an alcohol consumption per week of \<140 g; and other fatty liver-specific diseases caused by viral hepatitis or drug-induced hepatitis had been ruled out. A total of 68 patients undergoing CABG were divided into the NAFLD and the non-NAFLD control group. Other consumptive diseases were excluded in all patients enrolled and they all signed informed consent forms. All patients had complete clinical and pathological data and completed the treatment regimen. The patients were followed-up for 6 months after the procedure and the major adverse cardiac events were recorded, including death, myocardial infarction and angina pectoris. The study was approved by the Ethics Committee of the Second Affiliated Hospital of Xinjiang Medical University.

### CABG

All the patients enrolled received routine treatment for coronary heart disease, they all took a sufficient dose of enteric-coated aspirin and clopidogrel before the operation and the same dose of unfractionated heparin during the procedure, and they all underwent the multi-position projection after CABG to ensure the procedure had been successful.

### Collection and storage of samples

Peripheral venous blood (5 ml) were drawn from patients before and at 24 h and 1 month after the operation. After natural coagulation, the samples were centrifuged at 1,700 × g for 10 min. The serum was separated, quickly frozen, and stored in the freezer at −80°C for subsequent processing.

### Instruments and reagents

Innova-3100 full digital cardiovascular angiographic system (Thermo Fisher Scientific, Waltham, MA, USA).

### Detection of high-sensitivity C-reactive protein (hsCRP), soluble CD40 ligand (sCD40L), intercellular adhesion molecule-1 (ICAM-1) and matrix metalloproteinase-9 (MMP-9) in peripheral blood by enzyme-linked immunosorbent assay (ELISA)

Serum samples obtained from the patients were diluted 100 times in preparation for conventional ELISA tests. Standard and diluted serum samples (10 µl) were added onto each labeled reaction plate according to the instructions of the high-sensitivity hsCRP detection kit and the sCD40L detection kit (both from R&D Systems, Inc., Minneapolis, MN, USA), the ICAM-1 detection kit or the MMP-9 detection kit (both from Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Briefly, 100 µl conjugate reagent were added into each well, shaken slightly for 30 sec and incubated for 60 to 90 min at room temperature. The liquid in the reaction plate was shaken dry and phosphate-buffered saline (PBS; self-prepared by our laboratory) was added to wash the reaction plate 5 times. Horseradish peroxidase (HRP) was added and shaken slightly for 30 sec and incubated for 30 min at room temperature. The liquid in the reaction plate was shaken dry again, and PBS was added to wash the reaction plate 5 times. Then tetramethylbenzidine (TMB) developing solution was added for incubation at room temperature for 20 min. Finally, 100 µl of stop solution were added and shaken slightly for 30 sec, and the absorbance values of samples were measured using the microplate reader (450 nm). The contents of hsCRP, sCD40L, ICAM-1 and MMP-9 in samples in each group were calculated.

### Statistical analysis

The data in this study were presented as mean ± standard deviation. SPSS 19.0 software (SPSS, Inc., Chicago, IL, USA) was used for data analysis. t-test was used for intergroup comparisons, and analysis of variance was used for comparisons among groups. The homogeneity test of variance was performed and logistic regression analysis was used for the relationship between levels of inflammatory factors and the presence of postoperative adverse cardiovascular events. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### General data analysis

The clinicopathology data and treatment plans of patients before the CABG procedure were summarized. The results on [Table I](#tI-etm-0-0-5476){ref-type="table"} showed that there were no statistically significant differences in terms of age, sex, smoking history or preventive drug use between the patients in the NAFLD and the non-NAFLD groups (p\>0.05). Average alanine aminotransferase (ALT) levels in the NAFLD group were significantly higher than those in the non-NAFLD group, and the difference was statistically significant (p\<0.01).

Expression level of hsCRP in peripheral blood. The expression level of hsCRP in peripheral blood of patients was detected using an hsCRP kit. The results on [Table II](#tII-etm-0-0-5476){ref-type="table"} and [Fig. 1](#f1-etm-0-0-5476){ref-type="fig"} show that the expression levels of hsCRP in the NAFLD and non-NAFLD groups were significantly higher at 24 h after the CABG operation than before or one month after the procedure in each group (p\<0.01). However, there were no statistically significant differences in the expression levels of hsCRP before and at 1 month after the operation (p\>0.05); and also there were no statistically significant differences in the expression levels of hsCRP between the NAFLD and non-NAFLD groups (p\>0.05).

### Expression level of sCD40L in peripheral blood

The expression level of sCD40L in peripheral blood of patients was detected using a sCD40L kit. The results on [Table III](#tIII-etm-0-0-5476){ref-type="table"} and [Fig. 2](#f2-etm-0-0-5476){ref-type="fig"} show that the expression levels of sCD40L in NAFLD group and non-NAFLD group were highest at 24 h after operation in both groups (p\<0.01). However, there were no statistically significant differences in the expression levels of sCD40L before and at one month after the operation (p\>0.05); and there were no statistically significant differences in the expression levels of sCD40L between the NAFLD and non-NAFLD groups (p\>0.05).

### Expression level of ICAM-1 in peripheral blood

The expression level of ICAM-1 in peripheral blood of patients was detected using an ICAM-1 ELISA kit. The results shown on [Table IV](#tIV-etm-0-0-5476){ref-type="table"} and [Fig. 3](#f3-etm-0-0-5476){ref-type="fig"} reveal a slight increase in the expression levels of ICAM-1 one day after the CABG procedure in the two groups. But there was no statistically significant difference in the expression levels between the two groups before and after the operation (p\>0.05).

### Expression level of MMP-9 in peripheral blood

The expression level of MMP-9 in peripheral blood of patients was detected using an MMP-9 kit. The results in [Table V](#tV-etm-0-0-5476){ref-type="table"} and [Fig. 4](#f4-etm-0-0-5476){ref-type="fig"} show the expression levels of MMP-9 increased significantly after the operation and reached a peak one month after the procedure (p\<0.01). Importantly, the expression levels of MMP-9 in peripheral blood in the NAFLD group at 1 month after the CABG procedure were significantly higher than those in the non-NAFLD group (p\<0.01).

### Relationship between inflammatory factor levels in peripheral blood and prognosis

The number of adverse cardiovascular events was recorded for 6 months after the CABG operation through follow-up of patients. The results can be seen on [Table VI](#tVI-etm-0-0-5476){ref-type="table"}. The total incidence of adverse cardiovascular events of patients in the non-NAFLD group was significantly lower than that of patients in the NAFLD group (p=0.029). Logistic regression analysis was used to analyze the expression levels of hsCRP, sCD40L, ICAM-1 and MMP-9 in peripheral blood of patients and the rates of adverse cardiovascular events within 6 months after operation, and the results showed that the expression level of MMP-9 was an important influencing factor of cardiovascular events after CABG (OR=1.182, p\<0.05).

Discussion
==========

NAFLD can significantly increase the morbidity and mortality rates of coronary heart disease patients ([@b7-etm-0-0-5476]--[@b9-etm-0-0-5476]). The inflammatory response in vessels gets activated after bypass operation or coronary stenting, and leads to platelet aggregation and adhesion and further release of inflammatory mediators. Current studies have found that hsCRP, sCD40L, ICAM-1 and MMP-9 are commonly affected inflammatory factors ([@b10-etm-0-0-5476]--[@b12-etm-0-0-5476]). Investigating the relationship between the expression levels of inflammatory factors in peripheral blood after coronary bypass operation and the treatment outcomes in patients is important to be able to provide the patients with a more accurate prognosis.

CRP, an acute response albumin in the body, is an important factor in the inflammatory process, and is considered to be closely related to the occurrence, development and prognosis of coronary artery diseases. Studies have shown that CABG can cause vascular endothelial injury, and a series of cytokines get expressed during the process, such as CRP ([@b13-etm-0-0-5476]). CD40L is a surface glycoprotein that can be expressed in human atherosclerotic plaques and vascular endothelial cells ([@b14-etm-0-0-5476]). It was found in this study that hsCRP and sCD40L levels in peripheral blood of patients were increased 24 h after the CABG operation, and the levels were significantly higher than those before and at 1 month after the procedure (p\<0.01). This is consistent with a different study where it was found that after stenting, patients with coronary artery disease had increased expression levels of hsCRP in peripheral blood ([@b15-etm-0-0-5476]). Likewise, Napoleão *et al* ([@b16-etm-0-0-5476]) found that the expression levels of sCD40L were significantly increased in peripheral blood within 10 min after CABG compared with those before operation, suggesting that the levels may be associated with postoperative systemic inflammatory responses. Ma *et al* ([@b17-etm-0-0-5476]) showed that the expression levels of ICAM-1 increased slightly in peripheral blood of patients in the two groups after operation, but the differences were not statistically significant. The expression level of ICAM-1 of patients in NAFLD group almost had no change. This is inconsistent with literature reports where it was found that the ICAM-1 levels were increased when using a coronary artery injury model after CABG (may be due to the vascular damage response), or that the levels were low in other conditions (may be because of a negative feedback regulation mechanisms) ([@b18-etm-0-0-5476],[@b19-etm-0-0-5476]). Then again, it was found in this study that the expression levels of MMP-9 in peripheral blood of patients in the two groups were highest one day after the CABG procedure, and that the levels in the NAFLD group were significantly higher than those in the non-NAFLD group (p\<0.01). Furthermore, regression analysis showed that MMP-9 is an important influencing factor for adverse cardiovascular events after the bypass operation. These results are not surprising given that animal experiments had already proved that MMP-9 inhibitors can reduce restenosis after stenting, so it was suggested that MMP-9 and its inhibitors are involved in the development of in-stent restenosis ([@b20-etm-0-0-5476]). Based on these data, we believe that MMP-9 may be an important inflammatory mediator after coronary stenting, which is increased for a long time after the bypass operation for coronary heart disease in patients complicated with NAFLD, so it can be used as an inflammatory marker to predict adverse events of coronary heart disease in these patients.

In conclusion, the expression levels of inflammatory factors in peripheral blood of patients complicated with NAFLD undergoing CABG are different from those of non-complicated patients, and high levels of MMP-9 are associated with higher risk of adverse cardiovascular events after the operation. MMP-9 should be useful as an inflammatory marker for predicting the risk of adverse events for coronary heart disease patients complicated with NAFLD undergoing CABG procedures.
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###### 

Comparisons of general data of patients in the two groups before operation (mean ± standard deviation).

  Index                    NAFLD group   Non-NAFLD group   P-value
  ------------------------ ------------- ----------------- -----------------------------------------------------
  Sex (male/female)        14/17         16/21             0.382
  Age (years)              65.3±8.9      67.8±10.6         0.295
  History of smoking (%)   45.6%         42.7%             0.423
  Hypertension (%)         77.4%         67.6%             0.076
  Aspirin                  93.5%         94.6%             0.589
  ACEI drugs               51.6%         51.3%             0.657
  Statins                  96.8%         94.6%             0.569
  ALT (U/l)                69.32±11.26   25.65±7.52        0.008^[a](#tfn2-etm-0-0-5476){ref-type="table-fn"}^

Compared with non-NAFLD group

p\<0.01. NAFLD, non-alcoholic fatty liver disease; ALT, alanine aminotransferase.

###### 

Average hsCRP expression levels in peripheral blood of patients in the two groups.

                            hsCRP (ng/ml)                                              
  ------------------------- ---------------------------------------------------------- ----------------------------------------------------------
  Before operation          8.76±4.27                                                  8.25±3.82
  24 h after operation      16.27±5.52^[a](#tfn4-etm-0-0-5476){ref-type="table-fn"}^   15.96±6.26^[a](#tfn4-etm-0-0-5476){ref-type="table-fn"}^
  1 month after operation   9.27±5.13                                                  9.02±4.95

Compared with non-NAFLD group at each time-point

p\<0.01. hsCRP, high-sensitivity C-reactive protein; NAFLD, non-alcoholic fatty liver disease.

###### 

sCD40L expression levels in peripheral blood of patients in the two groups.

                            sCD40L (ng/ml)                                            
  ------------------------- --------------------------------------------------------- ---------------------------------------------------------
  Before operation          4.86±1.76                                                 4.51±1.32
  24 h after operation      9.25±2.01^[a](#tfn6-etm-0-0-5476){ref-type="table-fn"}^   8.97±2.38^[a](#tfn6-etm-0-0-5476){ref-type="table-fn"}^
  1 month after operation   5.29±2.48                                                 4.89±1.96

Compared with non-NAFLD group at each time-point

p\<0.01. sCD40L, soluble CD40 ligand; NAFLD, non-alcoholic fatty liver disease.

###### 

ICAM-1 expression levels in peripheral blood of patients in the two groups.

                            ICAM-1 (ng/ml)   
  ------------------------- ---------------- ------------
  Before operation          12.06±4.23       11.95±4.86
  24 h after operation      13.67±5.95       13.25±6.03
  1 month after operation   11.96±5.26       11.83±4.77

ICAM-1, intercellular adhesion molecule-1; NAFLD, non-alcoholic fatty liver disease.

###### 

MMP-9 expression levels in peripheral blood of patients in the two groups.

                            MMP-9                                                                                                    
  ------------------------- -------------------------------------------------------------------------------------------------------- ----------------------------------------------------------
  Before operation          17.52±3.86                                                                                               16.97±4.11
  24 h after operation      18.56±4.67                                                                                               18.22±4.35
  1 month after operation   40.18±5.51^[a](#tfn9-etm-0-0-5476){ref-type="table-fn"},[b](#tfn10-etm-0-0-5476){ref-type="table-fn"}^   30.02±6.15^[a](#tfn9-etm-0-0-5476){ref-type="table-fn"}^

Compared with non-NAFLD group at each time-point

p\<0.01; compared with non-NAFLD group

p\<0.01. MMP-9, matrix metalloproteinase-9; NAFLD, non-alcoholic fatty liver disease.

###### 

Percentages of adverse cardiovascular events in the two groups.

  Adverse cardiovascular events         NAFLD group   Non-NAFLD group   P-value
  ------------------------------------- ------------- ----------------- ------------------------------------------------------
  Death (%)                             3.2%          0                 0.356
  Angina pectoris                       9.7%          8.1%              0.187
  Myocardial infarction                 6.5%          5.4%              0.276
  Total adverse cardiovascular events   19.4%         13.5%             0.029^[a](#tfn12-etm-0-0-5476){ref-type="table-fn"}^

Compared with non-NAFLD group at each time-point

p\<0.05. NAFLD, non-alcoholic fatty liver disease.
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